Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN)

Squamous cell carcinoma of the head and neck (SCCHN) represents the sixth most common cancer globally and accounts for ∼5% of all cancers [1, 2]. The management of these cancers is complex and requires a multidisciplinary approach with multi-modality treatments but the survival outcome of these patients remain poor [2].